Skip to content
1 min left
0% read
Twenty Twenty Therapeutics logo

Twenty Twenty Therapeutics

Technology Company
South San Francisco, California, USA
Founded 2020
58

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Share:

Twenty Twenty Therapeutics

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics, and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Our vision is to eliminate preventable blindness. By transforming the delivery of today's eye care, we are improving patient access to intuitive and affordable diagnostics and treatments. We believe it should be easy for doctors to deliver superior outcomes to their patients.

Our technology empowers patients to care for their own vision in between doctors' visits. To accomplish these goals, we develop, market, and commercialize transformative innovations in diagnostics, sensing, and preventative, medical, and surgical treatments for eye diseases.

We were formed in August 2020 as a joint venture between Verily Life Sciences, an Alphabet company, and Santen, a leading Japanese pharmaceutical company. We are passionate and committed to building and sustaining an inclusive and equitable working environment. Every member of our team enriches our diversity by exposing us to a broad range of views that help us understand and engage with the world, identify challenges, and discover, design, and deliver solutions.

The Twenty Twenty work environment empowers our team to do their absolute best work.

Frequently Asked Questions About Twenty Twenty Therapeutics

Twenty Twenty Therapeutics is a software company. Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market.

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market. Our vision is to eliminate preventable blindness.

By transforming the del.

Twenty Twenty Therapeutics has been operating since 2020. You can verify their legitimacy through their official website and social media presence.

Twenty Twenty Therapeutics operates in the software sector of the cryptocurrency industry. Compare Twenty Twenty Therapeutics with other software companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Twenty Twenty Therapeutics, research their track record (operating since 2020), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Twenty Twenty Therapeutics is based in South San Francisco, California, USA, has been operating since 2020. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Twenty Twenty Therapeutics is based in South San Francisco, California, USA, North America, with offices in South San Francisco, California, USA.

Twenty Twenty Therapeutics was founded in 2020. The company currently has 58 employees.

Twenty Twenty Therapeutics Details

Twenty Twenty Therapeutics Offices (3)

Twenty Twenty Therapeutics Tags

More About Twenty Twenty Therapeutics

Work Model Details
Employees work from physical offices.

Latest from Academy

Why Venom Holders Stayed When The Price Crashed

Why Venom Holders Stayed When The Price Crashed

Venom (VENOM) is a Layer 1 sovereign-grade blockchain whose 2024 airdrop deliberately weighted token allocation toward testnet developers and contributors rather than wallet-volume farmers. Six months after distribution, the network logs 90,000 daily active users and 150,000-200,000 daily transactions while VENOM trades at $0.019, down 97.5% from its all-time high of $0.7824. OKX delisted VENOM in June 2025 and Bybit followed on April 7, 2026. Despite that liquidity loss, on-chain data shows base-tier recipients sold quickly while testnet contributors held; circulating supply sits at 988.9 million of 8 billion max. CEO Christopher Louis Tsu's team announced a post-quantum migration plan to ML-DSA and ML-KEM in April 2026, alongside x402 protocol integration for AI-agent payments. The thesis: builder-weighted airdrops produce stickier holder bases that survive price collapse, but only if the underlying tech finds product-market fit before patience runs out.

Archie Dutton logoArchie DuttonApr 29, 2026
8m
XRD Wallet Security Went From Afterthought to Industry Standard

XRD Wallet Security Went From Afterthought to Industry Standard

Radix (XRD) is a Layer 1 smart contract platform whose Babylon mainnet, live since September 28, 2023, makes blind signing structurally impossible at the wallet level. Network TVL climbed from $21.5M to $49.3M in fourteen days during March 2026, ranking the chain 51st on DefiLlama. The Babylon upgrade replaced encoded function calls with human-readable transaction manifests, a pattern now drawing attention in Cosmos and NEAR developer forums. Atlan Digital conducted a pre-launch security assessment; the chain has reported zero major exploits since launch. XRD trades at $0.001288 with a $17.28M market cap (#766 on CoinMarketCap). Founder Dan Hughes passed away unexpectedly in July 2025, with CEO Andy Jarrett now leading the Radix Foundation alongside Chief Strategy Officer Adam Simmons and Finance Director Jonathan Day. The thesis: Radix's transaction manifest design is becoming the reference pattern for minimum DeFi wallet security, even as XRD's market cap remains a footnote.

Mia Halland logoMia HallandApr 29, 2026
9m
HashKey Platform Token Makes Sense for One Type of Trader

HashKey Platform Token Makes Sense for One Type of Trader

HashKey Platform Token works like a loyalty card, not a lottery ticket. Trading at $0.17 and 93.8% below its all-time high of $2.56, HSK isn't a speculative moonshot. It's a utility token that makes economic sense in only one use case: traders already staked into HashKey's Exchange ecosystem who want reduced fees, staking access, and a regulated onramp into Hong Kong's crypto market.

7m